CHINESE MEDICAL JOURNAL

简称 CHINESE MED J-PEKING ·PEOPLES R CHINA ·出版周期 Monthly ·年均收录 411 篇

7.3

最新影响因子

8.80%

自引率

约55%

投稿难度

平均6.0个月

审稿周期

期刊简介

CHINESE MEDICAL JOURNAL是一本国际医学期刊，ISSN号为0366-6999，创刊于1887年，现为半月刊，出版地为中国北京，由中华医学会主办，出版商为Wolters Kluwer Health。该期刊2022年的影响因子为6.1，属于非开放获取（非OA）期刊，被SCI收录，在中科院分区中通常位于医学大类2区或3区。该杂志主要发表临床医学和基础医学领域的研究，涵盖内科、外科、儿科、神经科学等多个学科，特别关注中国及亚洲地区的高发疾病和特色诊疗技术。其发文特点包括原创研究、综述、病例报告和编者述评，注重研究的临床实用性和科学创新性。杂志质量较高，审稿流程严格，但作为非OA期刊，可能存在读者获取障碍的风险；此外，尽管影响因子稳步提升，但与国际顶尖医学期刊相比仍有差距，投稿时需注意其学术定位与自身研究的匹配度。

影响因子趋势

近期发表

Interaction of prepregnancy BMI and a history of gestational diabetes mellitus on the subsequent risk of the condition: A population-based cohort study 2026-09-10

Prognostic impact of quantitative CT-defined emphysema in lung cancer 2026-09-09

Ultrasound‑responsive nano‑contrast agents co‑delivering CIITA‑siRNA and rapamycin for targeted therapy against Hashimoto thyroiditis 2026-09-09

Complexity analysis of physiological signals in the wearable era: New insights into chronic diseases and aging 2026-09-09

Glycemic control and long-term macrovascular outcomes in people with type 2 diabetes in China 2026-09-09

Impact of intermittent hypoxia on cognitive impairment in sleep apnea models of rodents 2026-09-09

Mendelian randomization and machine learning reveal Streptococcaceae as a risk factor for rheumatoid arthritis 2026-09-09

Changing patterns and regional inequalities of asthma burden and attributable risks in China, 1990-2023 2026-09-04

Single-cell RNA sequencing uncovers m6A regulator-defined T-cell subpopulations and YTHDF1–HSP90AB1–MYC therapeutic axis in T-cell acute lymphoblastic leukemia 2026-09-01

Effectiveness and conversion outcomes of immune checkpoint inhibitors combined with lenvatinib and GEMOX chemotherapy as first-line treatment for advanced gallbladder cancer: A multicenter study 2026-09-01